MedTrace Logo

Vortioxetine for Binge Eating Disorder

NCT02528409 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 80

Last updated 2020-11-23

Study results available
· View outcomes & findings →

Summary

The aim of the present study is to examine the efficacy and safety of vortioxetine vs placebo in adults with moderate to severe Binge eating disorder, as indicated by at least 3 binge eating days per week for the 2 weeks before the baseline visit.

Conditions

  • Binge Eating Disorder

Interventions

DRUG

Vortioxetine

Medication currently approved for major depression.

DRUG

Placebo

Sponsors & Collaborators

  • Takeda

    collaborator INDUSTRY

  • University of Chicago

    lead OTHER

Principal Investigators

  • Jon E Grant, JD, MD, MPH · University of Chicago

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2016-06-30
Primary Completion
2018-11-30
Completion
2018-11-01

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02528409 on ClinicalTrials.gov